Concurrent Investment Advisors LLC Grows Stake in Sanofi (NASDAQ:SNY)

Concurrent Investment Advisors LLC increased its stake in shares of Sanofi (NASDAQ:SNY) by 2.6% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 37,946 shares of the company’s stock after buying an additional 973 shares during the quarter. Concurrent Investment Advisors LLC’s holdings in Sanofi were worth $1,830,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently made changes to their positions in the company. Charles Schwab Investment Management Inc. grew its holdings in shares of Sanofi by 31.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 139,505 shares of the company’s stock valued at $8,040,000 after buying an additional 33,105 shares during the last quarter. Arkadios Wealth Advisors grew its holdings in shares of Sanofi by 19.0% during the fourth quarter. Arkadios Wealth Advisors now owns 4,709 shares of the company’s stock valued at $227,000 after buying an additional 751 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Sanofi by 7.1% during the third quarter. Geode Capital Management LLC now owns 254,738 shares of the company’s stock valued at $14,681,000 after buying an additional 16,780 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Sanofi by 20.9% during the third quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company’s stock valued at $133,172,000 after buying an additional 399,301 shares during the last quarter. Finally, GFS Advisors LLC grew its holdings in shares of Sanofi by 1,017.9% during the third quarter. GFS Advisors LLC now owns 12,800 shares of the company’s stock valued at $738,000 after buying an additional 11,655 shares during the last quarter. 14.04% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on SNY shares. StockNews.com lowered shares of Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday, January 30th. Two analysts have rated the stock with a hold rating, one has issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $60.00.

Sanofi Trading Up 0.6 %

NASDAQ SNY opened at $54.46 on Friday. The company has a market capitalization of $138.21 billion, a PE ratio of 21.87, a P/E/G ratio of 1.00 and a beta of 0.57. The company has a fifty day moving average of $50.95 and a 200 day moving average of $52.52. Sanofi has a 1 year low of $45.22 and a 1 year high of $58.97. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14.

Sanofi (NASDAQ:SNY) last posted its earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. Research analysts forecast that Sanofi will post 4.36 earnings per share for the current year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.